share_log

Panbela Therapeutics | CORRESP: CORRESP

Panbela Therapeutics | CORRESP: CORRESP

Panbela Therapeutics | CORRESP:信函
美股sec公告 ·  04/15 12:45
Moomoo AI 已提取核心訊息
Panbela Therapeutics, Inc. has formally requested the Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, with the file number 333-278403. The company seeks to have the registration become effective on April 15, 2024, at 5:30 p.m. Eastern Time, or as soon thereafter as possible. This request was made in accordance with Rule 461 under the Securities Act of 1933. Panbela Therapeutics acknowledges its responsibilities related to the proposed public offering of securities as detailed in the Registration Statement. Any inquiries or comments regarding this acceleration request are to be directed to the company's counsel, Joshua L. Colburn of Faegre Drinker Biddle & Reath LLP.
Panbela Therapeutics, Inc. has formally requested the Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, with the file number 333-278403. The company seeks to have the registration become effective on April 15, 2024, at 5:30 p.m. Eastern Time, or as soon thereafter as possible. This request was made in accordance with Rule 461 under the Securities Act of 1933. Panbela Therapeutics acknowledges its responsibilities related to the proposed public offering of securities as detailed in the Registration Statement. Any inquiries or comments regarding this acceleration request are to be directed to the company's counsel, Joshua L. Colburn of Faegre Drinker Biddle & Reath LLP.
Panbela Therapeutics, Inc.已正式要求美國證券交易委員會(SEC)加快其S-1表格註冊聲明的生效日期,文件編號爲333-278403。該公司力求使註冊於美國東部時間2024年4月15日下午 5:30 生效,或此後儘快生效。該請求是根據1933年《證券法》第461條提出的。Panbela Therapeutics承認其與註冊聲明中詳述的擬議證券公開發行有關的責任。有關此加速請求的任何詢問或評論均應提交給該公司的法律顧問,即Faegre Drinker Biddle & Reath LLP的約書亞·科爾本。
Panbela Therapeutics, Inc.已正式要求美國證券交易委員會(SEC)加快其S-1表格註冊聲明的生效日期,文件編號爲333-278403。該公司力求使註冊於美國東部時間2024年4月15日下午 5:30 生效,或此後儘快生效。該請求是根據1933年《證券法》第461條提出的。Panbela Therapeutics承認其與註冊聲明中詳述的擬議證券公開發行有關的責任。有關此加速請求的任何詢問或評論均應提交給該公司的法律顧問,即Faegre Drinker Biddle & Reath LLP的約書亞·科爾本。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息